COVID-19 spotlights the critical need for Datacubed’s remote and flexible electronic clinical outcomes assessment technology
Advanced mHealth technology firm offers study teams infection identification solutions in real-time
Datacubed Health’s Paul Glimcher and Jenn Cho discuss how geofencing technology can drastically reduce missing data in clinical trials.
Janssen has selected Datacubed Health to provide geofencing technology solutions in order to detect patient hospitalizations in clinical trials.
Datacubed Health today launches the Linkt Location app, which tracks participant interactions with health care facilities, providing reminders and other communications to garner insight into health events that are often unreported.
Datacubed Health today announced the launch of Linkt Location, a unique technology solution that allows pharmaceutical companies, clinical research organizations (CROs) and other healthcare providers to accurately detect significant health events that often go undetected with existing data capture methods.
With virtual health transforming the entire healthcare landscape, pharma is leveraging digital health tools to improve its processes.
Today’s mostly paper-dependent clinical trials pose fundamental challenges to the pharmaceutical industry. Such trials can be prohibitively expensive, struggle to enroll and retain a sufficient number of participants, and have difficulty maintaining compliance and data reliability. But with the advent of virtual and partially virtual trials using digital tools and devices, we have the opportunity to substantially improve efficiency by deploying the same design principles that make consumer apps so successful.
How close are we to personalizing healthcare? This was the theme of MM&M and Deloitte Digital’s aptly named event, Humanizing the Health Experience, which took place at Deloitte Digital’s downtown NYC offices earlier this month.
Scientists with the Dominantly Inherited Alzheimer Network (DIAN) at the Washington University in St. Louis School of Medicine are undertaking five years of studies of a rare form of early-onset Alzheimer’s disease using a “bring your own device” (BYOD) study model.